1
|
Yilmaz AF, Saydam G, Sahin F and Baran Y:
Granulocytic sarcoma: A systematic review. Am J Blood Res.
3:265–270. 2013.PubMed/NCBI
|
2
|
Avni B and Koren-Michowitz M: Myeloid
sarcoma: Current approach and therapeutic options. Ther Adv
Hematol. 2:309–316. 2011. View Article : Google Scholar : PubMed/NCBI
|
3
|
Bakst RL, Tallman MS, Douer D and Yahalom
J: How I treat extramedullary acute myeloid leukemia. Blood.
118:3785–3793. 2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW:
The 2016 revision to the World Health Organization classification
of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405.
2016. View Article : Google Scholar : PubMed/NCBI
|
5
|
Patnaik MM, Parikh SA, Hanson CA and
Tefferi A: Chronic myelomonocytic leukaemia: A concise clinical and
pathophysiological review. Br J Haematol. 165:273–286. 2014.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Fraser S, Roberts L and Murphy E: Cauda
equina syndrome: A literature review of its definition and clinical
presentation. Arch Phys Med Rehabil. 90:1964–1968. 2009. View Article : Google Scholar : PubMed/NCBI
|
7
|
Bickley LS and Szilagyi PG: BATES' Pocket
Guide to Physical Examination and History Taking. 5th. Lippincott
Williams & Wilkins; Philadelphia: pp. 3132007
|
8
|
Such E, Germing U, Malcovati L, Cervera J,
Kuendgen A, Porta MG Della, Nomdedeu B, Arenillas L, Luño E, Xicoy
B, et al: Development and validation of a prognostic scoring system
for patients with chronic myelomonocytic leukemia. Blood.
121:3005–3015. 2013. View Article : Google Scholar : PubMed/NCBI
|
9
|
Kaloostian PE, Yurter A, Zadnik PL,
Sciubba DM and Gokaslan ZL: Current paradigms for metastatic spinal
disease: An evidence-based review. Ann Surg Oncol. 21:248–262.
2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Coleman RE: Skeletal complications of
malignancy. Cancer 80 (8 Suppl). 1588–1594. 1997. View Article : Google Scholar
|
11
|
Parikh SA and Tefferi A: Chronic
myelomonocytic leukemia: 2013 update on diagnosis, risk
stratification, and management. Am J Hematol. 88:967–974. 2013.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Mathew RA, Bennett JM, Liu JJ, Komrokji
RS, Lancet JE, Naghashpour M, Messina JL, List AF, Moscinski LC and
Zhang L: Cutaneous manifestations in CMML: Indication of disease
acceleration or transformation to AML and review of the literature.
Leuk Res. 36:72–80. 2012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Bradford CR, Smith SR and Wallis JP:
Pericardial extramedullary haemopoiesis in chronic myelomonocytic
leukaemia. J Clin Pathol. 46:674–675. 1993. View Article : Google Scholar : PubMed/NCBI
|
14
|
Craig JW and Lin RJ: Paraneoplastic
autoimmunity associated with testicular myeloid sarcoma and chronic
myelomonocytic leukemia. Case Rep Hematol.
2013:6565432013.PubMed/NCBI
|
15
|
Fukushima M, Ono Y and Imai Y:
Granulocytic sarcoma of the small intestine in a patient with
chronic myelomonocytic leukemia. Dig Endosc. 26:757–758. 2014.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Hyams ES, Gupta R, Melamed J, Taneja SS
and Shah O: Renal involvement by chronic myelomonocytic leukemia
requiring nephroureterectomy. Rev Urol. 11:33–37. 2009.PubMed/NCBI
|
17
|
Wilson DB, Michalski JM, Grossman WJ and
Hayashi RJ: Isolated CNS relapse following stem cell
transplantation for juvenile myelomonocytic leukemia. J Pediatr
Hematol Oncol. 25:910–913. 2003. View Article : Google Scholar : PubMed/NCBI
|
18
|
Silverman LR, McKenzie DR, Peterson BL,
Holland JF, Backstrom JT, Beach CL and Larson RA: Cancer and
Leukemia Group B: Further analysis of trials with azacitidine in
patients with myelodysplastic syndrome: Studies 8421, 8921, and
9221 by the Cancer and Leukemia Group B. J Clin Oncol.
24:3895–3903. 2006. View Article : Google Scholar : PubMed/NCBI
|